Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Rhea-AI Summary

Purple Biotech (NASDAQ: PPBT) will present new preclinical data from its CAPTN-3 conditionally activated tri-specific antibody platform at ESMO-IO 2025 in London on December 10, 2025. The poster (FPN# 287P) led by Dr. Hadas Reuveni highlights two novel CAPTN-3 platform compounds and preclinical anti-tumor activity, including data in multiple PD-1 resistant models and evidence of engagement of T cells and NK cells against tumor-associated antigens. Management said the findings demonstrate platform versatility and synergy in treatment-resistant cancers. The poster will be posted in the company's Publications section after the congress.

News Market Reaction

+7.99%

5 alerts

+7.99% News Effect

+4.2% Peak in 4 hr 50 min

+$571K Valuation Impact

$8M Market Cap

0.7x Rel. Volume

On the day this news was published, PPBT gained 7.99%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $571K to the company's valuation, bringing the market cap to $8M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share price: $0.822 Volume today: 10,563,154 shares Avg 20-day volume: 261,871 shares +5 more

8 metrics

Share price $0.822 Before CAPTN-3 ESMO-IO 2025 data announcement

Volume today 10,563,154 shares Trading day of Dec 4, 2025

Avg 20-day volume 261,871 shares Pre-news average liquidity

52-week high $5.20 52-week range before ESMO-IO news

52-week low $0.5326 52-week range before ESMO-IO news

Cash & deposits $10.5M As of Sept 30, 2025 (Q3 2025 results)

Operating loss $1.4M Q3 2025 operating loss

R&D expenses $0.6M Q3 2025, 56% decrease YoY

Market Reality Check

Price: $0.6640 Vol: Volume 10,563,154 vs 20-d...

high vol

$0.6640 Last Close

Volume Volume 10,563,154 vs 20-day average 261,871 (relative volume 40.34) highlights unusually heavy trading ahead of the ESMO-IO data. high

Technical Shares at 0.822 are trading below the 200-day MA of 1.86 and remain 84.19% under the 52-week high.

Peers on Argus

Sector peers show mixed moves (e.g., PBM up 5.44%, GTBP down 7.14%), and no peer...

Sector peers show mixed moves (e.g., PBM up 5.44%, GTBP down 7.14%), and no peers appeared in the momentum scanner, indicating the reaction to PPBT’s CAPTN-3 data update was stock-specific rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Conference data news	Positive	+8.0%	Announcement of CAPTN-3 preclinical data presentation at ESMO-IO 2025.
Nov 14	Earnings and update	Positive	-3.0%	Q3 2025 results with cash runway to 1H 2027 and pipeline progress.
Oct 29	Pipeline milestone	Positive	+81.8%	IM1240 manufacturing milestone validating CAPTN-3 scalability and process.
Oct 20	Listing compliance	Negative	-0.4%	Nasdaq minimum bid price notice and 180-day cure period disclosure.
Sep 10	IP and patent news	Positive	-5.3%	Intention to grant European patent for NT219 immunotherapy combinations.

Pattern Detected

CAPTN-3 platform milestones have previously triggered strong upside moves, while patent and earnings updates have sometimes seen negative price reactions despite constructive messaging.

Recent Company History

Over the past few months, Purple Biotech has highlighted progress across its pipeline and corporate profile. On Sep 10, it reported an intention to grant a European patent for NT219 combinations, but shares fell 5.28%. A Nasdaq minimum bid price notice on Oct 20 had a modest -0.4% impact. In contrast, an IM1240 manufacturing milestone from the CAPTN-3 platform on Oct 29 drove an 81.82% jump. Q3 2025 results on Nov 14 saw a -2.95% move. Earlier coverage of the same CAPTN-3 ESMO-IO poster showed a 7.99% rise.

Market Pulse Summary

The stock moved +8.0% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +8.0% in the session following this news. A strong positive reaction aligns with prior CAPTN-3 milestones, such as the 81.82% move on the IM1240 manufacturing update and the earlier 7.99% gain on this same ESMO-IO poster news. However, past divergence on constructive events like patents and earnings suggests sentiment can be volatile. The company’s small market cap of $7.456M and listing-compliance overhang may also influence the durability of any move.

Key Terms

tri-specific antibodies, tumor associated antigens, t cells, nk cells, +2 more

6 terms

tri-specific antibodies medical

"CAPTN-3 platform of conditionally activated tri-specific antibodies"

Tri-specific antibodies are specially designed proteins that can attach to three different targets at the same time. Think of them as multi-tool connectors that can engage multiple parts of a disease process, potentially making treatments more effective. For investors, these innovative therapies could lead to new medical options and growth opportunities in the healthcare sector.

tumor associated antigens medical

"engage T cells, NK cells and bind to tumor associated antigens"

Tumor associated antigens are molecules found on the surface of cancer cells that are different from those on normal cells. They can trigger the body's immune response and are often targeted in cancer treatments. For investors, these antigens matter because they influence the development of diagnostic tools and therapies that could impact the value of biotech and pharmaceutical companies involved in cancer care.

t cells medical

"tri-specific antibodies that engage T cells, NK cells and bind"

T cells are a type of immune system cell that help the body identify and fight infections and abnormal cells. They act like security guards, recognizing threats and triggering responses to eliminate them. In the context of health and medicine, T cells are important because their activity can influence disease outcomes and treatments, which can impact investor interest in biotech and healthcare sectors.

nk cells medical

"tri-specific antibodies that engage T cells, NK cells and bind"

Natural killer (NK) cells are a type of immune system cell that helps the body defend itself against threats like viruses and cancer by quickly identifying and destroying abnormal cells. Their activity can influence overall health and disease progression, which may impact market sectors related to healthcare and biotechnology. Understanding NK cells provides insight into how the body responds to illnesses that can affect economic and investment landscapes.

pd-1 resistant medical

"data from our lead CAPTN-3 program, IM1240, in multiple PD-1 resistant models"

PD‑1 resistant describes a cancer that no longer responds to PD‑1 inhibitor drugs, a class of immunotherapy that helps the immune system recognize and attack tumor cells. Like weeds that survive a once-effective herbicide, resistant tumors keep growing despite treatment, which matters to investors because it reduces the market size for existing drugs, drives demand for follow-up therapies or combination treatments, and influences clinical trial design and approval risk.

tumor immune evasion medical

"therapies that seek to overcome tumor immune evasion and drug resistance"

Tumor immune evasion is the process by which cancer cells develop ways to avoid detection and destruction by the body's immune system. Think of it like a burglar wearing a disguise to slip past security; the cancer cells hide their presence to survive and grow unchecked. This ability to evade immune defenses can impact the effectiveness of certain cancer treatments and influence overall health outcomes, making it a key factor in medical research and drug development.

AI-generated analysis. Not financial advice.

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers
    
REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom.    

Presentation Details: 

●    Conference: ESMO Immuno-Oncology (ESMO-IO) 2025 Annual Congress
●    Title: CAPTN-3 unique design demonstrated by 2 novel platform compounds
●    Presenter: Dr. Hadas Reuveni
●    Presentation Number: FPN# 287P
●    Session Title: Poster Presentation
●    Date/Time: Wednesday, December 10, 2025, 17:15
●    Location: London, UK

“Our CAPTN-3 platform can produce novel tri-specific antibodies that engage T cells, NK cells and bind to tumor associated antigens. The powerful synergy we have seen in preclinical studies strengthens our conviction in not only the platform, but also in this novel structure to overcome tumor evasion and drug resistance. We look forward to showcasing new data from our lead CAPTN-3 program, IM1240, in multiple PD-1 resistant models, and new data demonstrating the platform versatility with multiple tri-specific antibodies” said Gil Efron, Chief Executive Officer of Purple Biotech, Ltd.

The poster will be accessible under the Publications section of the Purple Biotech website following the congress.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes CAPTN-3, CM24 and NT219. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound’s therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophil extracellular traps is a novel target for the treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers and other potential tissue biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients with NT219 in combination with cetuximab or pembrolizumab was initiated. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com 

CONTACTS:

IR@purple-biotech.com

FAQ

When and where will Purple Biotech (PPBT) present CAPTN-3 data at ESMO-IO 2025?

Purple Biotech will present on December 10, 2025 at 17:15 during a poster session (FPN# 287P) in London.

What does the CAPTN-3 presentation for PPBT cover at ESMO-IO 2025?

The poster covers two novel CAPTN-3 tri-specific platform compounds and preclinical anti-tumor activity, including results in PD-1 resistant models.

Which Purple Biotech program is highlighted in the CAPTN-3 ESMO-IO 2025 poster?

The company highlighted its lead CAPTN-3 program, IM1240, with data reported in multiple PD-1 resistant preclinical models.

How can investors access Purple Biotech's CAPTN-3 poster after ESMO-IO 2025?

The poster will be available under the Publications section of Purple Biotech's website following the congress.

What mechanism does Purple Biotech claim for the CAPTN-3 tri-specific antibodies (PPBT)?

The company describes CAPTN-3 tri-specific antibodies as engaging T cells and NK cells while binding tumor-associated antigens, designed to address tumor immune evasion.